Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another solid day as an illiquid pos.
Dollar volume w/ this pos is non-existent.
It's been dead since they filed their s-1. Where's all the volume and liquidity?
YW
Dog chit + dog chit = ?
Still need help w/ the answer?
Pumptastic!!!
Dog chit + dog chit = Dog chit(s)
Tpia + ehvvf = ?
Need help solving?
NASDAQ symbol will be PSLY
circling back....
live & learn...
Dog chit + dog chit = more dog chit
Tpia + ehvvf = ?
Need help solving?
Grabbed some more of this good stuff before merger close.
Asking .65
Only 1000 shares left and blast off time!!!
PSLY.com already filed its S-4
https://www.sec.gov/Archives/edgar/data/1931373/000109690622001995/psly_s4.htm
.....TPIA rocket is being fueled as we speak
Ei.Ventures files 1-A with SEC
https://www.benzinga.com/secfilings/22/09/29006124/ei-ventures-inc-form1-sa
Dog chit + dog chit = dog chit
Tpia + ehvvf = ?
Who needs help solving?
Market about to break below June lows
Could see more pain in microcaps as June lows get taken out
Cleary you haven't looked at these shills behind this dog chit.
I dont care what these guys put in any legal docs, it's all bs that will fail & most likely never get executed.
Even if they form the new company and get listed on Nasdaq, they'll take it to zero.
Exactly what they've done with other shells in the past, currently worth zero.
Believe whatever you'd like.
GL
Gw
Your comments are baseless. I posted Ei Ventures' S-4, which is a legal document they filed with the SEC. Even if you think Mycotopia is "POS," as you call it, Ei outlined everything in the S-4. TPIA and Ei are both going to be gone. They are applying to NASDAQ for listing of PSLY. TPIA serves the purpose of getting Ei/PSLY to NASDAQ quicker than doing a registration statement. I gave you the page number and the direct quote. TPIA s up 74% today on $150,000 in volume in the first hour and a half of trading, so I'm not sure where you get it will "be small money due to lack of volume and attn?" Also, TPIA has only been public since May 2021. Not four years.
There'll be some potential for quick flip trades, but it'll be small money due to lack of volume and attn.
Hope it works out for traders here, but this pos will never be investment quality.
Been following these shills for several years now (4+). They will use and abuse shareholders w/o question.
They've never executed on a single thing, so I've continued to waive a caution flag.
GLTA
Gw
It looks like he's going to cloes this one at $1.56 a share. That's why the stock is moving higher. Page 53 of Ei's S-4 says "In connection with the amendment of the LOI, the parties filed a press release on December 7, 2021 disclosing the amended LOI. The amended LOI provided that the valuation of Mycotopia’s shares for purposes of the merger agreement would be fixed at the value on the trading day prior to the press release, which was $1.56 per share."
https://www.sec.gov/Archives/edgar/data/1931373/000109690622001995/psly_s4.htm
TPIA & EHVVF same ceo
Which one? TPIA or Ei Ventures?
Ceo has never closed any proposed LOI or definitive agreement, ever.
All lies. All of the time.
Or incompetence.
Either way, don't count on anything "real" from these scumbags.
Caution, imo
GLTA
GW
hope it comes thru its dropped so much ugh
I did too. I spoke with the company and the merger with Ei is still on.
good grief man
Wow 1.50 to 3.27?? Posted to twitter just as fast.
https://twitter.com/momsbottom/status/1527325117147013142?s=21&t=FGMSjhRtM8Bxj2BalPokPg
Agreed. Home run here
300 mill news title, 1.2 mill float.. no brainer
Agree, 2.11's super thin
TPIA
Looking to add here!
TPIA
IMO this has plenty of growing room with the sector expected to grow 3 fold in the next few years
TPIA
That is a hefty increase
TPIA
2.35 nhod up in power hour!
TPIA
The global market for psych-e-delics is expected to triple from $2.077B in 2019 to a staggering $6.859B by 2027.
TPIA
I was looking at that as well, I agree, Could be a nice day for TPIA
Should see a nice move back to the 50ma!
TPIA
Hot sector here: psych-e-delics are the next big thing in the
$1.3 Trillion Pharmaceutical Market
TPIA
Way undervalued at these levels, 2.20's thin on the ask!
TPIA
With innovative collaborations, TPIA stands to be first and strongest to market with the greatest chance of long-term growth.
TPIA
Looking forward to watching this progress TPIA
Not a scam. Ei.Ventures raised $25 million in a Reg A https://www.ei.ventures. They sent an email to all of their Reg A subscribers and said they were cutting it off their Reg A on March 22, which they did. Ei.Ventures also said they would be moving ahead with the merger with TPIA. Here's a recent video discussing it.
Hopefully different than ehave, but history suggests caution.
Same ceo.
Scam/fake LOI ANNOUNCED today
CEO has history of never executing on any LOI.
Look at ehave.
$TPIA Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression
https://www.globenewswire.com/news-release/2021/11/17/2336391/0/en/Mycotopia-Therapies-Announces-Plan-to-Develop-Psychedelic-Sublingual-Tablet-to-Help-Treat-Depression.html
MIAMI, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today it has initiated plans for a psilocybin-based pharmaceutical program by entering into an agreement to form a 50/50 joint venture (the “Joint Venture”) with Agile Pharmaceutical Solutions to develop novel oral dosage forms of psilocybin in the form of a psychedelic sublingual tablet. The two parties plan to attain a Health Canada License for psychedelics to obtain and test psychedelic raw material, for the purpose of creating the psilocybin-based, sublingual tablet to take to market.
Mycotopia Therapies and Agile Pharmaceutical Solutions plan to conduct oversight and development of the tablet in Jamaica and explore the possibility of partnering with Havn Life Sciences (CSE: HAVN) (OTC Pink: HAVLF) in Jamaica for raw materials and developing the tablet. In August Mycotopia Therapies, Inc. announced it had entered into a Psilocybin Supply Agreement with Havn Life Sciences to purchase naturally-derived psilocybin. Should the Joint Venture be granted Health Canada Psychedelics License, the terms of the agreement call for moving the operations to Canada for final testing to prove efficacy of the tablet.
Sublingual tablets are placed under the tongue. There, they dissolve rapidly beneath the tongue and enter directly into the tiny blood vessels beneath. Via these capillaries, sublingual drugs can enter the bloodstream much more quickly than oral medications. Sublingual tablets dispense the full amount of medication directly into the bloodstream without experiencing liver metabolism. As a result, physicians can prescribe smaller dosages that are guaranteed to reach their intended target. Because a sublingual dose of medicine is administered and absorbed under the tongue, it bypasses the stomach and its contents on its way to the bloodstream. As a result, sublingual drugs do not interact with foods and other medications before absorption. The dosage does not cause or experience interference by other medications and does not cause the gastrointestinal irritation of some oral medications. Individuals who have trouble swallowing or have pill aversions sometimes avoid taking medications due to the stress caused by oral medications. Sublingual versions of the same medicines can make taking prescription medications much easier, as the tablet does not need to be swallowed.
Moe Harati, Ph.D., Founder & CEO of Agile Pharmaceuticals Solutions Inc., said, "This partnership will help us to combine forces and help people live a longer healthier happier life by utilizing Agile Pharma’s intellectual property & expertise in developing innovative high-quality products and Mycotopia’s outreach and resources."
Prof. Dr. Bankole Johnson, Medical Advisor to Mycotopia Therapies‘ Board, said, “An interesting development, which may allow future further exploration of psychedelics to treat psychiatric disorders.” Bankole A. Johnson, DSc, MD, MPhil, FRCPsych is a licensed physician and board-certified psychiatrist throughout Europe and the United States who served as Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia. Dr. Johnson's primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism.
In October 2018, the Food and Drug Administration granted Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder. Breakthrough designation allows for an accelerated pathway to approval. Currently, psilocybin is classified as a Schedule I drug in the US as it has not been approved by the FDA for any therapeutic use. According to the National Institute of Mental Health an estimated 19.4 million adults in the United States had at least one major depressive episode. This number represented 7.8% of all U.S. adults. Recent statistics from the World Health Organization show 3.8% of the world's population, approximately 280 million people, have depression. At its worst, depression can lead to suicide. Over 700 000 people die due to suicide every year. Suicide is the fourth leading cause of death in 15-29-year-olds.
Ben Kaplan, CEO of Mycotopia Therapies said, "This opportunity to develop a psychedelic sublingual tablet using the intellectual property of Agile Pharmaceutical Solutions is a tremendous opportunity for Mycotopia Therapies. The real opportunity, however, is derived from our two companies working together toward the common goal of revolutionizing how mental illness is treated. The sublingual administration presents an opportunity to possibly set a new standard for psychedelic assisted therapy.”
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
127
|
Created
|
03/16/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |